<DOC>
	<DOCNO>NCT01328106</DOCNO>
	<brief_summary>The purpose study determine whether GSK1120212 , MEK inhibitor , effective safe treatment cancer subject metastatic uveal melanoma mutation-positive GNAQ GNA11 metastatic melanoma .</brief_summary>
	<brief_title>Efficacy Safety Study GSK1120212 , MEK Inhibitor , Subjects With Uveal Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Uveal Neoplasms</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Histologically cytologically confirm diagnosis metastatic uveal melanoma previously document mutationpositive GNAQ GNA11 metastatic melanoma previously treat MEK inhibitor . Provide archival tumor tissue , tissue block available , undergo fresh tumor biopsy prior enrollment . The patient radiographically measurable tumor . ECOG performance status 0 , 1 , 2 . The patient able swallow retain oral medication . Life expectancy least 4 month . Toxicities previous anticancer therapy ( except alopecia ) recover ( Grade 1 less ) time enrollment . The patient adequate organ bone marrow function . Sexually active patient must use medically acceptable method contraception course study . Female patient childbearing potential must negative serum pregnancy test screening . The patient follow within 21 day start study drug anticipates need follow course study treatment : chemotherapy , immunotherapy , biologic therapy , hormone therapy , major surgery , tumor embolization . The patient receive experimental therapy within 21 day start study drug . The patient receive nitrosourea mitomycin C within 42 day start study drug . The patient receive herbal medication palliative radiotherapy within 14 day start study drug . The patient currently receive anticoagulation therapy well control . Ongoing newly diagnose eye abnormality symptom due uveal melanoma . History retinal vein occlusion central serous retinopathy . Current severe , uncontrolled systemic disease . History leptomeningeal disease spinal cord compression secondary metastasis . Brain metastasis , unless previously treat surgery , wholebrain radiation stereotactic radiosurgery disease stable least 3 month without steroid use stable dose steroid least 1 month prior start study drug . Stability brain metastasis must confirm imaging . The patient concurrent , active hematological malignancy solid tumor malignancy . History clinically significant cardiac pulmonary dysfunction . Allergy hypersensitivity component GSK1120212 formulation . The patient pregnant breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>